Document is current

Article History

Received: 30 November 2021

Accepted: 21 March 2022

First Online: 6 April 2022

Declarations

:

: The Department of Intensive Care Medicine of the Inselspital has, or has had in the past, research contracts with Abionic SA, AVA AG, CSEM SA, Cube Dx GmbH, Cyto Sorbents Europe GmbH, Edwards Lifesciences LLC, GE Healthcare, ImaCor Inc., MedImmune LLC, Orion Corporation, and Phagenesis Ltd.; and research and development/consulting contracts with Edwards Lifesciences LLC, Nestec SA, and Wyss Zurich. The money was paid into a departmental fund; Drs. Berger, Bloch, and Bachmann received no personal financial gain and declare that they have no personal conflict of interest. The Department of Intensive Care Medicine of the Inselspital has received unrestricted educational grants from the following entities for the organization of a quarterly postgraduate educational symposium, the Berner Forum for Intensive Care (until 2015): Abbott AG, Anandic Medical Systems, Astellas, AstraZeneca, Bard Medica SA, Baxter, B | Braun, CSL Behring, Covidien, Fresenius Kabi, GSK, Lilly, Maquet, MSD, Novartis, Nycomed, Orion Pharma, Pfizer, and Pierre Fabre Pharma AG (formerly known as RobaPharm). It has received unrestricted educational grants from the following entities for the organization of biannual postgraduate courses in the fields of critical care ultrasound and the management of ECMO and mechanical ventilation: Abbott AG, Anandic Medical Systems, Bard Medica SA., Bracco, Dräger Schweiz AG, Edwards Lifesciences AG, Fresenius Kabi (Schweiz) AG, Getinge Group Maquet AG, Hamilton Medical AG, Pierre Fabre Pharma AG (formerly known as RobaPharm), PanGas AG Healthcare, Pfizer AG, Orion Pharma, and Teleflex Medical GmbH. Drs. Bloechlinger, Wigger, De Marchi, Kurmann, Stalder, and Grübler have no conflict of interest to declare.

: The study was approved by the Ethics Committee of the Canton of Bern (KEK 104/14). Patients provided written informed consent prior to enrollment.

: Not applicable.